Vanguard Group
VIRX

Vanguard Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Vanguard Group’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-289,174
Closed -$46.6K – 4339
2024
Q4 		$46.6K Sell
289,174
-665,311
-70% -$131K ﹤0.01% 4219
2024
Q3 		$220K Sell
954,485
-206,795
-18% -$75.8K ﹤0.01% 4122
2024
Q2 		$631K Hold
1,161,280
– – ﹤0.01% 3930
2024
Q1 		$1.18M Hold
1,161,280
– – ﹤0.01% 3757
2023
Q4 		$662K Buy
1,161,280
+13,368
+1% +$8.2K ﹤0.01% 3955
2023
Q3 		$1.19M Hold
1,147,912
– – ﹤0.01% 3765
2023
Q2 		$1.62M Hold
1,147,912
– – ﹤0.01% 3732
2023
Q1 		$1.83M Hold
1,147,912
– – ﹤0.01% 3711
2022
Q4 		$1.68M Buy
1,147,912
+33,544
+3% +$98K ﹤0.01% 3728
2022
Q3 		$4.76M Buy
1,114,368
+207,108
+23% +$877K ﹤0.01% 3357
2022
Q2 		$3.52M Buy
907,260
+78,383
+9% +$223K ﹤0.01% 3550
2022
Q1 		$3.94M Sell
828,877
-625,449
-43% -$1.88M ﹤0.01% 3641
2021
Q4 		$5.31M Buy
1,454,326
+9,711
+0.7% +$51.8K ﹤0.01% 3573
2021
Q3 		$11.6M Buy
1,444,615
+10,693
+0.7% +$105K ﹤0.01% 3155
2021
Q2 		$16.3M Buy
1,433,922
+1,225,874
+589% +$12.3M ﹤0.01% 2938
2021
Q1 		$1.92M Buy
208,048
+111,611
+116% +$1.16M ﹤0.01% 3869
2020
Q4 		$671K Buy
96,437
+9,117
+10% +$47.6K ﹤0.01% 3909
2020
Q3 		$382K Sell
87,320
-33,047
-27% -$289K ﹤0.01% 3852
2020
Q2 		$1.11M Sell
120,367
-1,625
-1% -$24.5K ﹤0.01% 3587
2020
Q1 		$1.77M Buy
121,992
+3,931
+3% +$85.3K ﹤0.01% 3342
2019
Q4 		$1.4M Hold
118,061
– – ﹤0.01% 3545
2019
Q3 		$2.98M Buy
118,061
+52,821
+81% +$1.52M ﹤0.01% 3310
2019
Q2 		$1.66M Buy
65,240
+45,348
+228% +$1.75M ﹤0.01% 3523
2019
Q1 		$846K Buy
19,892
+7,999
+67% +$181K ﹤0.01% 3670
2018
Q4 		$173K Sell
11,893
-19,647
-62% -$802K ﹤0.01% 3926
2018
Q3 		$2.21M Sell
31,540
-435
-1% -$33K ﹤0.01% 3495
2018
Q2 		$2.37M Sell
31,975
-1,351
-4% -$120K ﹤0.01% 3448
2018
Q1 		$3.17M Buy
33,326
+4,383
+15% +$752K ﹤0.01% 3306
2017
Q4 		$3.74M Buy
28,943
+11,705
+68% +$1.1M ﹤0.01% 3244
2017
Q3 		$1.17M Sell
17,238
-69
-0.4% -$5.63K ﹤0.01% 3550
2017
Q2 		$1.64M Buy
17,307
+680
+4% +$78.1K ﹤0.01% 3442
2017
Q1 		$2.39M Buy
16,627
+4,314
+35% +$617K ﹤0.01% 3327
2016
Q4 		$1.56M Buy
12,313
+1,124
+10% +$156K ﹤0.01% 3446
2016
Q3 		$1.71M Sell
11,189
-714
-6% -$101K ﹤0.01% 3437
2016
Q2 		$1.37M Buy
11,903
+101
+0.9% +$11.2K ﹤0.01% 3514
2016
Q1 		$1.34M Buy
11,802
+1,600
+16% +$243K ﹤0.01% 3508
2015
Q4 		$1.92M Buy
10,202
+612
+6% +$114K ﹤0.01% 3409
2015
Q3 		$1.63M Buy
9,590
+1,379
+17% +$498K ﹤0.01% 3464
2015
Q2 		$5.19M Buy
8,211
+24
+0.3% +$12.8K ﹤0.01% 3001
2015
Q1 		$4.21M Buy
8,187
+513
+7% +$259K ﹤0.01% 3077
2014
Q4 		$4.11M Buy
7,674
+736
+11% +$332K ﹤0.01% 2998
2014
Q3 		$10.4M Buy
6,938
+631
+10% +$914K ﹤0.01% 2472
2014
Q2 		$8.64M Buy
6,307
+310
+5% +$360K ﹤0.01% 2567
2014
Q1 		$8.32M Buy
5,997
+917
+18% +$1.07M ﹤0.01% 2574
2013
Q4 		$5.06M Buy
5,080
+536
+12% +$554K ﹤0.01% 2797
2013
Q3 		$4.73M Buy
4,544
+11
+0.2% +$11.8K ﹤0.01% 2775
2013
Q2 		$4.96M Buy
+4,533
New +$5.05M ﹤0.01% 2669

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Vanguard Group's VIRX Position: Q1 2025 in Review

Vanguard Group sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 289,174 shares — an estimated $46.6K sold.

Vanguard Group first reported a position in VIRX in Q2 2013 and held it in 47 quarters. The position peaked at $16.3M in Q2 2021. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Vanguard Group reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Vanguard Group sold 289,174 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $46.6K.
  • Vanguard Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 47 quarters.
  • Vanguard Group's Viracta Therapeutics, Inc. Common Stock position peaked at $16.3M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Vanguard Group's 13F filing for Q1 2025, filed 9 May 2025.